National Cancer Survivors Day '97

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 5
Volume 6
Issue 5

FRANKLIN, Tenn--National Cancer Survivors Day 1997, the world's largest cancer survivor event, is set for Sunday, June 1. This 10th anniversary Celebration of Life will recognize America's 7.4 million cancer survivors and those who support them.

FRANKLIN, Tenn--National Cancer Survivors Day 1997, the world'slargest cancer survivor event, is set for Sunday, June 1. This10th anniversary Celebration of Life will recognize America's7.4 million cancer survivors and those who support them.

More than 650 communities throughout the nation will hold celebrationson June 1. The National Cancer Survivors Day Foundation, whichsupports the celebration, recognizes a "survivor" asanyone living with a history of cancer, from the time of diagnosisthrough the remainder of life.

The day means "picnics and parades, concerts and carnivals,tree plantings, building camaraderie, and sharing survivor stories,"the Foundation said in a press release.

"National Cancer Survivors Day means that I'm not alone,"said Rae Marie Bozzo, a newly diagnosed breast cancer survivorfrom New Jersey. "It means that I have a lot of company andcan go to meetings with others who share my experience, whichI find uplifting."

The celebration had its beginnings in Kansas City when cancersurvivor Richard Bloch (co-founder of H&R Block) and his wifeAnnette held their first Cancer Survivor Rally to obtain mediacoverage that would demonstrate that a diagnosis of cancer isnot an automatic death sentence.

Recent Videos
The approval of daratumumab validates the notion of using limited therapy to help delay progression from smoldering disease to multiple myeloma.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
A simulation procedure helped to ascertain chemotherapy tolerability before administering radioembolization therapy for NETs with liver metastases.
The addition of radioembolization to radiosensitizing chemotherapy may help concurrently treat patients with liver tumors and disease outside the liver.
In neuroendocrine tumor management, patients with insulinoma may be at risk of severe hypoglycemia following receipt of GLP-1 receptor agonists.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
4 experts are featured in this series.
4 experts are featured in this series.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
7 experts are featured in this series.
Related Content